<p>隨着美國市場連續第四個交易日上漲，受益於超出預期的 GDP 增長和科技行業的反彈，市場的關注點轉向那些能夠在這些動態條件下應對的高增長科技股。在這種環境中，識別有前景的股票需要評估它們在應對經濟變化和技術進步方面的創新潛力和適應能力。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Cellebrite DI</td>
<td>15.29%</td>
<td>20.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 75 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些潛在的投資機會。</p>
<h2>ADMA Biologics (ADMA)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ADMA Biologics, Inc. 是一家生物製藥公司，專注於開發、生產和營銷用於治療免疫缺陷和傳染病的特殊血漿衍生生物製劑，市值為 46.6 億美元。</p>
<p><strong>運營：</strong> ADMA Biologics 主要通過其生物製造部門產生收入，該部門的收入為 4.8164 億美元，而其血漿採集中心貢獻了 677 萬美元。</p>
<p>ADMA Biologics 展現出強勁的財務表現，過去一年盈利增長顯著，達到 207.4%，遠超行業增長。這一趨勢得到了 23% 的年盈利增長預測和 19.6% 的年收入增長的支持，均超過市場平均水平。公司的戰略研發投資至關重要，與其收入相結合，促進了創新並保持了在生物科技領域的競爭優勢。最近，ADMA 提高了 2025 年和 2026 年的財務預測，同時通過今年 2301 萬美元的積極股票回購繼續提升股東價值。這些舉措反映了在動態市場條件下擴大運營和潛在確保長期增長的積極態度。</p>
<ul>
<li>解鎖我們對 ADMA Biologics 股票分析的全面見解，請查看本健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 ADMA Biologics 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f89ca4c1-8d8c-472e-b71e-3bd45378af08/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f89ca4c1-8d8c-472e-b71e-3bd45378af08/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ADMA 收入和支出明細</p>
<h2>CarGurus (CARG)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> CarGurus, Inc. 運營一個在線汽車平台，促進美國及國際範圍內的車輛買賣，市值約為 36.9 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其美國市場部門產生收入，該部門的收入為 8.0172 億美元，數字批發部門的收入為 5035 萬美元。</p>
<p>CarGurus 展現出顯著的扭轉局面，今年實現盈利，淨收入為 1.0611 億美元，而去年則出現淨虧損。這一轉變得益於 22.4% 的年盈利增長，超過美國市場平均水平的 16.2%。公司在研發和產品創新方面的戰略重點體現在其最近推出的 PriceVantage，這是一種利用實時數據優化經銷商定價策略的定價解決方案。該工具已經使參與的經銷商在週轉時間上顯著超越競爭對手。此外，CarGurus 今年的股票回購總額達到 2.9523 億美元，反映了其對股東價值的承諾和對持續增長的信心，儘管其收入預測的增長速度（每年 6.3%）低於市場（10.7%）。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 CarGurus 的潛力。</li>
<li>查看 CarGurus 的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de4c7c87-7486-4613-8996-bf1d7d679595/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de4c7c87-7486-4613-8996-bf1d7d679595/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 CARG 收入和支出明細</p>
<h2>Roku (ROKU)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Roku, Inc. 運營一個電視流媒體平台，覆蓋美國及國際市場，市值約為 160.8 億美元。</p>
<p><strong>運營：</strong> Roku 主要通過其平台部門產生收入，該部門的收入為 39.6 億美元，遠超其設備部門的 5.8713 億美元。</p>
<p>Roku 在競爭激烈的流媒體行業中的發展軌跡以戰略創新和合作夥伴關係為標誌，旨在增強其市場地位並應對行業挑戰。最近，Roku 報告了顯著的扭轉，第三季度銷售額達到 12.1 億美元，較去年同期的 10.6 億美元增長，反映出 11% 的年收入增長，超過美國市場平均水平的 10.7%。這一增長伴隨着盈利能力的轉變，淨收入達到 2481 萬美元，而去年同期則出現虧損。此外，Roku 與 DoubleVerify 的合作在打擊連接電視廣告中的廣告欺詐方面發揮了關鍵作用，展示了其在平台上確保和提升廣告質量的承諾。這些努力通過最近的財報結果和戰略聯盟得到了強調，不僅增強了 Roku 的收入來源，還鞏固了其在數字廣告領域的地位，為未來的增長奠定了堅實的基礎。</p>
<ul>
<li>在這裏深入瞭解 Roku 的具體情況，查看我們的詳細健康報告。</li>
<li>通過我們的歷史業績報告評估 Roku 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/744f6447-c3ab-4606-b8bc-5bdfa4635280/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/744f6447-c3ab-4606-b8bc-5bdfa4635280/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ROKU 收入和支出細分</p>
<h2>總結</h2>
<ul>
<li>點擊這裏訪問我們完整的 75 只美國高增長科技和人工智能股票索引。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並及時獲取股票的關鍵更新提醒。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用。</li>
</ul>
<h2>準備探索其他投資風格嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，得到分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是人形的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可達。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

新美亞電子

ADMA生物制藥

MRKR

PLTR

<p>美國市場因強勁的 GDP 增長和科技行業的反彈而出現上漲。投資者正關注高增長的科技股，評估它們的創新能力和適應性。頂尖公司包括 Marker Therapeutics、Sanmina 和 Palantir Technologies 等。ADMA Biologics、CarGurus 和 Roku 因其財務表現和戰略舉措而受到關注。ADMA 顯示出強勁的盈利增長，CarGurus 已實現盈利，而 Roku 則通過戰略合作伙伴關係提升其市場地位</p>

<p>As the United States market experiences a fourth consecutive session of gains, buoyed by better-than-expected GDP growth and a tech sector rally, attention turns to high-growth tech stocks that are poised to navigate these dynamic conditions. In this environment, identifying promising stocks involves assessing their potential for innovation and adaptability in response to economic shifts and technological advancements.</p>
<div class="lb-trans"><p>隨着美國市場連續第四個交易日上漲，受益於超出預期的 GDP 增長和科技行業的反彈，市場的關注點轉向那些能夠在這些動態條件下應對的高增長科技股。在這種環境中，識別有前景的股票需要評估它們在應對經濟變化和技術進步方面的創新潛力和適應能力。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Cellebrite DI</td>
<td>15.29%</td>
<td>20.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Cellebrite DI</td>
<td>15.29%</td>
<td>20.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 75 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 75 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些潛在的投資機會。</p>
</div><h2>ADMA Biologics (ADMA)</h2>
<div class="lb-trans"><h2>ADMA Biologics (ADMA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.66 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ADMA Biologics, Inc. 是一家生物製藥公司，專注於開發、生產和營銷用於治療免疫缺陷和傳染病的特殊血漿衍生生物製劑，市值為 46.6 億美元。</p>
</div><p><strong>Operations:</strong> ADMA Biologics generates revenue primarily through its biomanufacturing segment, which accounts for $481.64 million, while its plasma collection centers contribute $6.77 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> ADMA Biologics 主要通過其生物製造部門產生收入，該部門的收入為 4.8164 億美元，而其血漿採集中心貢獻了 677 萬美元。</p>
</div><p>ADMA Biologics has demonstrated robust financial performance, with a notable 207.4% surge in earnings over the past year, significantly outpacing the industry's growth. This trend is complemented by an impressive forecast of 23% annual earnings growth and a revenue increase at 19.6% annually, both exceeding market averages. The company's strategic R&amp;D investments have been pivotal, aligning with its revenue to foster innovation and maintain competitive advantage in the biotech sector. Recently, ADMA raised its fiscal projections for 2025 and 2026 while continuing to enhance shareholder value through aggressive share repurchases totaling $23.01 million this year. These actions reflect a proactive approach in scaling operations and potentially securing long-term growth amidst dynamic market conditions.</p>
<div class="lb-trans"><p>ADMA Biologics 展現出強勁的財務表現，過去一年盈利增長顯著，達到 207.4%，遠超行業增長。這一趨勢得到了 23% 的年盈利增長預測和 19.6% 的年收入增長的支持，均超過市場平均水平。公司的戰略研發投資至關重要，與其收入相結合，促進了創新並保持了在生物科技領域的競爭優勢。最近，ADMA 提高了 2025 年和 2026 年的財務預測，同時通過今年 2301 萬美元的積極股票回購繼續提升股東價值。這些舉措反映了在動態市場條件下擴大運營和潛在確保長期增長的積極態度。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of ADMA Biologics stock in this health report.</li>
<li>Evaluate ADMA Biologics' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 ADMA Biologics 股票分析的全面見解，請查看本健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 ADMA Biologics 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f89ca4c1-8d8c-472e-b71e-3bd45378af08/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/f89ca4c1-8d8c-472e-b71e-3bd45378af08/chart/revenue-and-expenses-breakdown"/></p>
<p>ADMA Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ADMA 收入和支出明細</p>
</div><h2>CarGurus (CARG)</h2>
<div class="lb-trans"><h2>CarGurus (CARG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> CarGurus, Inc. operates an online automotive platform facilitating the buying and selling of vehicles both in the United States and internationally, with a market cap of approximately $3.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CarGurus, Inc. 運營一個在線汽車平台，促進美國及國際範圍內的車輛買賣，市值約為 36.9 億美元。</p>
</div><p><strong>Operations:</strong> The company primarily generates revenue from its U.S. Marketplace segment, which accounts for $801.72 million, complemented by its Digital Wholesale segment at $50.35 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其美國市場部門產生收入，該部門的收入為 8.0172 億美元，數字批發部門的收入為 5035 萬美元。</p>
</div><p>CarGurus has demonstrated a significant turnaround, becoming profitable this year with a net income of $106.11 million compared to a net loss last year. This shift is underscored by robust earnings growth at 22.4% annually, outpacing the US market average of 16.2%. The company's strategic focus on R&amp;D and product innovation is evident in its recent launch of PriceVantage, a pricing solution that leverages real-time data to optimize dealership pricing strategies effectively. This tool has already enabled engaged dealers to significantly outperform competitors in turn times. Additionally, CarGurus' proactive share repurchases, totaling $295.23 million this year, reflect its commitment to shareholder value and confidence in sustained growth despite its revenue forecast growing at a slower pace (6.3% annually) compared to the market (10.7%).</p>
<div class="lb-trans"><p>CarGurus 展現出顯著的扭轉局面，今年實現盈利，淨收入為 1.0611 億美元，而去年則出現淨虧損。這一轉變得益於 22.4% 的年盈利增長，超過美國市場平均水平的 16.2%。公司在研發和產品創新方面的戰略重點體現在其最近推出的 PriceVantage，這是一種利用實時數據優化經銷商定價策略的定價解決方案。該工具已經使參與的經銷商在週轉時間上顯著超越競爭對手。此外，CarGurus 今年的股票回購總額達到 2.9523 億美元，反映了其對股東價值的承諾和對持續增長的信心，儘管其收入預測的增長速度（每年 6.3%）低於市場（10.7%）。</p>
</div><ul>
<li>Take a closer look at CarGurus' potential here in our health report.</li>
<li>Examine CarGurus' past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 CarGurus 的潛力。</li>
<li>查看 CarGurus 的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de4c7c87-7486-4613-8996-bf1d7d679595/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/de4c7c87-7486-4613-8996-bf1d7d679595/chart/revenue-and-expenses-breakdown"/></p>
<p>CARG Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 CARG 收入和支出明細</p>
</div><h2>Roku (ROKU)</h2>
<div class="lb-trans"><h2>Roku (ROKU)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market capitalization of approximately $16.08 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Roku, Inc. 運營一個電視流媒體平台，覆蓋美國及國際市場，市值約為 160.8 億美元。</p>
</div><p><strong>Operations:</strong> Roku generates revenue primarily through its Platform segment, which accounts for $3.96 billion, significantly exceeding the $587.13 million from its Devices segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> Roku 主要通過其平台部門產生收入，該部門的收入為 39.6 億美元，遠超其設備部門的 5.8713 億美元。</p>
</div><p>Roku's trajectory in the competitive streaming sector is marked by strategic innovations and partnerships aimed at enhancing its market position and addressing industry challenges. Recently, Roku reported a significant turnaround with third-quarter sales reaching $1.21 billion, up from $1.06 billion the previous year, reflecting an 11% annual revenue growth which outpaces the US market average of 10.7%. This growth is complemented by a shift to profitability, with net income hitting $24.81 million compared to a loss in the same period last year. Additionally, Roku's collaboration with DoubleVerify has been pivotal in combating ad fraud within connected TV advertising, showcasing its commitment to secure and enhance advertising quality on its platform. These efforts are underscored by recent earnings results and strategic alliances that not only bolster Roku’s revenue streams but also fortify its standing in the digital advertising realm, setting a robust foundation for future growth.</p>
<div class="lb-trans"><p>Roku 在競爭激烈的流媒體行業中的發展軌跡以戰略創新和合作夥伴關係為標誌，旨在增強其市場地位並應對行業挑戰。最近，Roku 報告了顯著的扭轉，第三季度銷售額達到 12.1 億美元，較去年同期的 10.6 億美元增長，反映出 11% 的年收入增長，超過美國市場平均水平的 10.7%。這一增長伴隨着盈利能力的轉變，淨收入達到 2481 萬美元，而去年同期則出現虧損。此外，Roku 與 DoubleVerify 的合作在打擊連接電視廣告中的廣告欺詐方面發揮了關鍵作用，展示了其在平台上確保和提升廣告質量的承諾。這些努力通過最近的財報結果和戰略聯盟得到了強調，不僅增強了 Roku 的收入來源，還鞏固了其在數字廣告領域的地位，為未來的增長奠定了堅實的基礎。</p>
</div><ul>
<li>Dive into the specifics of Roku here with our thorough health report.</li>
<li>Assess Roku's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 Roku 的具體情況，查看我們的詳細健康報告。</li>
<li>通過我們的歷史業績報告評估 Roku 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/744f6447-c3ab-4606-b8bc-5bdfa4635280/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/744f6447-c3ab-4606-b8bc-5bdfa4635280/chart/revenue-and-expenses-breakdown"/></p>
<p>ROKU Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ROKU 收入和支出細分</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click here to access our complete index of 75 US High Growth Tech and AI Stocks.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 75 只美國高增長科技和人工智能股票索引。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並及時獲取股票的關鍵更新提醒。</li>
<li>Simply Wall St 是您解鎖全球市場趨勢的關鍵，是一款面向前瞻性投資者的免費用户友好應用。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>準備探索其他投資風格嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，得到分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是人形的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可達。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

High Growth Tech Stocks To Watch In US December 2025

- 美國科技股因 GDP 增長和市場反彈繼續走強。  
- ADMA Biologics 和 CarGurus 業績突出，顯示創新潛力。  
- Roku 聚焦廣告質量提升，實現盈利和收入增長。

2025 年 12 月美國值得關注的高增長科技股票